Models To Predict The Short-Term Survival of Acute-On-Chronic Liver Failure Patients Following Liver Transplantation

Min Yang

Third Xiangya Hospital of Central South University

Bo Peng

Third Xiangya Hospital of Central South University

Quan Zhuang

Third Xiangya Hospital of Central South University

Junhui Li

Third Xiangya Hospital of Central South University

Hong Liu

Third Xiangya Hospital of Central South University

Ke Cheng

Third Xiangya Hospital of Central South University

Yingzi Ming (✉ mingyz_china@csu.edu.cn)

Third Xiangya Hospital of Central South University

Research Article

Keywords: ACLF, machine-learning models, liver transplantation, prognosis, MELD

Posted Date: November 18th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-1066854/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background: Acute-on-chronic liver failure (ACLF) is featured with rapid deterioration of chronic liver disease and poor short-term prognosis. Liver transplantation (LT) is recognized as the curative option for ACLF. However, there is no standard in the prediction of the short-term survival among ACLF patients following LT.

Method: Preoperative data of 132 ACLF patients receiving LT at our center were investigated retrospectively. Cox regression was performed to determine the risk factors for short-term survival among ACLF patients following LT. Five conventional score systems (the MELD score, ABIC, CLIF-C OFs, CLIF-SOFAs and CLIF-C ACLFs) in forecasting short-term survival were estimated through the receiver operating characteristic (ROC). Four machine-learning (ML) models, including support vector machine (SVM), logistic regression (LR), multi-layer perceptron (MLP) and random forest (RF), were also established for short-term survival prediction.

Results: Cox regression analysis demonstrated that creatinine (Cr) and international normalized ratio (INR) were the two independent predictors for short-term survival among ACLF patients following LT. The ROC curves showed that the area under the curve (AUC) ML models was much larger than that of conventional models in predicting short-term survival. Among conventional models the model for end stage liver disease (MELD) score had the highest AUC (0.704), while among ML models the RF model yielded the largest AUC (0.940).

Conclusion:

Compared with the traditional methods, the ML models showed good performance in the prediction of short-term prognosis among ACLF patients following LT and the RF model perform the best. It is promising to optimize organ allocation and promote transplant survival based on the prediction of ML models.

Introduction

Acute-on-chronic liver failure (ACLF) is a syndrome with acute exacerbation of chronic hepatopathy, characterized by intense systemic inflammation, multiple organ dysfunction, and poor prognosis[1]. Liver transplantation (LT) is regarded as the curative method for terminal liver diseases including ACLF [2, 3]. However, there is considerable discrepancy between the increasing ACLF patients waiting for LT and the shortage of available organ donors, and the 1-year post-transplantation mortality rate of ACLF still reaches approximately 20%[4]. Consequently it is necessary to establish the selection criteria of ACLF for LT, which may improve organ allocation and transplant outcome.

In previous studies, several scoring systems were applied to forecast the short-term outcome among ACLF patients. The model for end stage liver disease (MELD) score accurately evaluates the liver conditions and prognosis of terminal stage hepatopath, including ACLF, which had important

implications for organ-allocation in emergency [5]. However, some studies have indicated a weak association between pre-transplant MELD score and post-transplant survival [6, 7]. The predictive value of other scores directed at ACLF, including the Chronic Liver Failure Consortium Organ Failure scores (CLIF-C OFs), CLIF sequential organ failure assessment scores (CLIF-SOFAs) and CLIF Consortium ACLF scores (CLIF-C ACLFs), has also been validated in ACLF patients[8–10]. However, few studies revealed these scores have good predictive value for short-term outcome in ACLF patients following LT. Therefore, it is essential to generate a new accurate prediction model for postoperative survival of ACLF following LT.

Machine learning (ML) leverages software algorithms to identify patterns in large data sets to establish predictive models more precisely than conventional methods. Machine learning algorithms can find novel patterns between variables and generate predictions by learning from multiple features simultaneously[11]. Several recent studies have indicated that ML models are useful for improving organ allocation and the transplant outcome after LT [12–15]. Previously my team had applied eight ML models for tacrolimus dose requirement post kidney transplantation [16]. The application of ML models is promising to forecast the short-term transplant survival of ACLF patients, which may contribute to organ allocation and benefit prognosis.

In the study, my team retrospectively analyzed ACLF patients receiving LT in our institution, and comparing the predictive value of conventional models and ML models for predicting 90-day posttransplant survival of these patients based on preoperative variables.

Methods

Study Design

A retrospective study was designed to develop ML models to make a prediction for short-term prognosis in ACLF patients following LT. ACLF patients undergoing LT were enrolled from the Transplantation Center, Third Xiangya Hospital, Central South University between March, 2012 and December, 2019. The study protocol complied with the standards of the Declaration of Helsinki and obtained approval from the Institutional Review Board of Third Xiangya Hospital, Central South University (No. 2020-S398).

Patients

Liver grafts with <30% macrovesicular steatosis from donation after cardiac death (DCD) were all approved and distributed by China Organ Transplant Response System (COTRS). All recipients were administered Basiliximab as intraoperative induction therapy. The standard maintenance immunosuppressions consisted of calcineurin inhibitors (CNIs; tacrolimus or cyclosporin), mycophenolate mofetil or mycophenolate sodium (MMF), and prednisone. According to the criteria of the Asian Pacific Association for the Study of the Liver (APASL), ACLF was defined as “acute hepatic insult manifesting as jaundice (serum bilirubin > 5 mg/dL) and coagulopathy (INR > 1.5), complicated within 4 weeks by ascites and/or encephalopathy in a patient with previously diagnosed or undiagnosed chronic

liver disease”[17]. Preoperative variables including clinical characteristics and biochemical parameters were collected and analyzed. All ACLF patients’ preoperative clinical data were used to calculate five conventional prediction formulas (the MELD score, ABIC, CLIF-C OFs, CLIF-SOFAs and CLIF-C ACLFs). The details of the formulas for the scores are shown in Supplement Table 1. All patients provided informed consent to participate in the study.

Model building

Four ML classifiers were employed to predict 90-day post-transplant survival based on the patient’s preoperative variables: Support vector machine (SVM), logistic regression (LR), multilayer perceptron (MLP) and random forest (RF). The ML models were trained to build a prediction model using fivefold cross-validation and implemented via Python programming language (version 3.6) and Scikit-learn package (version 0.22) as previously reported [18]. In order to estimate the performance of different ML models, we applied k-fold cross-validation (with $k = 5$) and selected the good hyperparameters. In general, 132 patients were divided at random into five subgroups. A single subgroup is retained as the validation cohort for testing the final selected model while 4 subgroups are used as derivation cohort to create a formula. The average area under the curve (AUC) was computed by five independent runs. Finally, the algorithms were developed in the full data set of the eligible group.

According to the SVM model, the function was $f(x) = \text{SIGN}(\beta_0 + \beta_m x_m)$. As the value was 1, the patient was divided into the death group. As the value was -1, the patient was divided into the survival group. According to the LR model, the function was $f(x) = \text{SIGMOID}(\beta_0 + \beta_m x_m)$. As the value was over 0.5, the patient was divided into the death group. As the value was no more than 0.5, the patient was divided into the survival group. The RF model was built with ten trees. Each tree in the forest is trained using a diverse portion of the database. Majority voting was performed obtain the final predictions.

Statistical analysis

Descriptive statistics are represented using means $\pm$ standard deviations (SD) or interquartile range (IQR) for continuous data and percentages for count data. Preoperative data were compared by Student’s t-test, the Pearson Chi-squared or Fisher exact test as appropriate. Kaplan-Meier (KM) survival curves and Cox regression analysis were made to analyze the risk factors for 90-day prognosis among ACLF patients following LT. The predictive power of conventional score systems for 90-day outcome was estimated by the receiver operating characteristic (ROC) curve. Results of $p < 0.05$ were thought to be significant and statistical calculations were performed using in SPSS version 22.0 (SPSS, Inc., Chicago, IL, USA).

Results

Basic characteristics

A total of 271 patients accepted LT at our institution between March 1st, 2012 and December 31st, 2019, of which 132 patients achieving the APASL criteria of ACLF were eligible for this study. The flowchart for

inclusion is shown in Figure 1. Nineteen ACLF patients (14.4%) died within 90 days after liver transplantation. The causes of death were upper gastrointestinal bleeding (n=7, 36.8%), multiple organ dysfunction syndrome (MODS) (n=6, 31.5%), severe pneumonia (n=3, 15.8%), abdominal infection (n=1, 5.3%), heart arrest (n=1, 5.3%) and cerebral herniation (n=1, 5.3%).

Comparison of clinical data between the survival group and the death group displayed no statistical difference in terms of age, sex, etiology, total bilirubin (TbIL), creatinine (Cr), international normalized ratio (INR), hepatic encephalopathy (HE), prothrombin time (PT), urea, albumin, direct bilirubin (DBIL), hemoglobin, platelet count, white blood cells (WBC), neutrophil count (NEUT) and lymphocyte count (LYM) (Table 1).

Patient survival analysis

Based on traditional formulae scores, the cut-off values of the important score-related parameters (Cr, INR, TbIL, Plt and WBC) were determined, which were applied for Kaplan-Meier (KM) survival analysis. The results indicated that the post-transplant mortality among ACLF patients was significantly associated with higher values of Cr ($\text{Cr} \geq 132.6 \mu\text{mol/L}$) and INR ($\text{INR} \geq 2.0$) ($P < 0.05$). The differences among other factors were not statistically significant (Figure 2).

The model of Cox regression was applied to identify the independent risk factors for short-term outcome. Univariate Cox regression analysis revealed that Cr ($P = 0.001$) and INR ($P = 0.034$) were poor prognostic indicators for ACLF patients following LT. Factors with $P < 0.15$ were further analyzed in multivariate cox regression. The results of multivariate analysis displayed that Cr (HR, 1.006; 95% CI, 1.001–1.011; $P = 0.030$) and INR (HR, 1.454; 95% CI, 1.100–1.921; $P = 0.009$) were independent prognostic markers of short-term outcome (Table 2).

Predictive value of conventional models

In comparison to those in the survival group, the scores of conventional models, including the MELD score, ABIC, CLIF-C OFs, CLIF-SOFAs, and CLIF-C ACLFs were higher in the death group. However, only MELD score ($P = 0.01$) and CLIF-C ACLFs ($p = 0.04$) showed significance between the survival group and death group (Figure 2 and Table 3). According to the ROC analysis, the area under a receiver operating characteristics (AUROC) of MELDs (AUROC: 0.704) was higher than those of ABIC (AUROC: 0.607), CLIF-C OFs (AUROC: 0.606), CLIF-C ACLFs (AUROC: 0.653), and CLIF-SOFAs (AUROC: 0.633) for prediction of the 90-day outcome in ACLF patients following LT (Figure 3).

Predictive value of ML models

Four ML models (SVM, LR, MLP and RF) were trained and compared to improve the prediction performance. All ML models had good performance in terms of AUROC (Figure 3), higher than those of conventional models. Among the ML models, the RF model had the highest AUROC of 0.94. The final result of RF model was derived from majority voting by the ten trees. The AUROCs of SVM, LR and MLP were 0.81, 0.83 and 0.89, respectively. Cr, INR, etiology, DBiL, LYM and NEUT were chosen to develop the

SVM and LR models. The coefficients of parameters in the models are described in Table 4. In the two models, the coefficients of Cr and INR are negative, indicating a negative correlation with the prognosis in ACLF patients following LT. The other parameters including etiology of liver disease, DBIL, LYM and NEUT, are positively associated with transplant outcome.

Discussion

This study successfully established four ML models for forecasting the short-term prognosis of ACLF patients following LT. Overall, the ML model had better performance than the conventional models, and the RF model best predicted the short-term survival of ACLF patients following LT. ML algorithms could be a useful tool, which might contribute to better organ allocation and transplant outcomes.

It is well reported that there are several conventional models available to accurately estimate liver function and prognosis of chronic hepatopathy patients, such as Child–Pugh scores and the MELD. The allocation of donor Liver according to the recipient's MELD score is to prioritize the sickest candidates awaiting LT and to minimize wait-list mortality [5, 19]. The MELD score is an accepted clinical prediction model for evaluating 3- to 6-month survival in patients with hepatic failure [19]. However, ACLF has a unique clinical feature, and the predictor of MELD score for ACLF patients is not ideal. Liang Chen et al. exhibited that the ABIC score performed better than the MELD score in forecasting short-term survival among HBV-related ACLF patients [20]. Novel predictive assessment models (CLIF-C OFs, CLIF-SOFAs and CLIF-C ACLFs) have been developed and validated to forecast mortality in patients with ACLF, among which the CLIF-C ACLFs achieved better predictive accuracy than the MELD score [4].

The great majority of previous researchers concluded that the MELD score and its exceptions had a limited ability to predict post-transplant mortality [21]. The MELD score could be correlated with post-transplant survival, but the pre-transplant MELD score appeared to have limited predictive ability [6]. No further studies showed that CLIF-C OFs, CLIF-SOFAs and CLIF-C ACLFs had good predictive value for short-term survival after LT. Our study indicated that the MELD score had a better AUROC (0.704) than other conventional models, but they all showed poor discrimination power in predicting postoperative survival.

Compared with traditional methods, ML algorithms utilize artificial intelligence to generate predictive models more precisely through the simultaneous detection of multidimensional parameters simultaneously [11]. The training set is employed to perform feature selection and parametric estimation, and the validation set is applied to assess the predictive power of the models. Furthermore, the model has the ability to self-evolve to adjust its structure when any errors are encountered. The models are promising in big data analysis, with the improvement of models performance using more data. Lau L et al. reported that RF model based on 15 donor and recipient variables had an excellent AUROC of 0.818 in forecasting the risk of liver graft failure in LT, thereby providing further evidence that the application of ML tools contributes to improving organ allocation decisions and transplant outcomes [12]. Hyung-Chul Lee et al. applied seven ML methods to predicting acute kidney injury (AKI) after LT and the gradient

boosting machine model exhibited the best performance with the AUROC of 0.90 [14]. Our team developed ML methods to confirm the relation between peripheral lymphocyte subsets and pneumonia among kidney transplant recipients for better individualized therapy [18]. Therefore, the ML technique could be a powerful and promising means in the evaluating of the prognosis of ACLF following LT. Our results showed that ML models had a better performance than conventional models, and RF model had the highest AUROC. These models were based on easily obtained parameters in clinic, making them practical in application.

Despite a growing number of LT performed in China over the years, there remains increasing discrepancy between the need for transplantation and the availability of donor organs. LT is considered a life-saving treatment for ACLF patients. The current policy for organ allocation in LT is to give priority to the sickest patients mostly using MELD score in ranking. It is difficult to consider whether the ACLF patient has a favorable prognosis following LT. Use of ML will dramatically enhance the efficiency of allocation of DCD organs for LT and contribute to maximal organ utilization. The selected preoperative variables in this study consisted of five parameters, namely, Cr, INR, etiology of liver disease, DBiL, LYM and NEUT. In our study, multivariate Cox regression modeling identified that Cr and INR were distinct prognostic factors of poor short-term survival in association with ACLF following LT. Cr is the most important component of the MELD score, which can objectively reflect the severity of chronic hepatopathy and prioritize liver transplants. Moreover, some research data indicated that higher values of Cr were correlated with the poor prognoses of chronic hepatopathy patients and LT recipients [19, 22]. First, pretransplant renal function was associated with renal insufficiency and worse short-term survival following LT [23, 24]. The occurrence of pretransplant renal function injury may result in an increase incidence of kidney failure and permanent kidney damage after LT [25]. Second, LT candidates with renal dysfunction confront with higher mortality risk from cardiovascular disease (CVD) after LT. Previous research indicated that pretransplant renal impairment was an independent indicator of post-LT CVD mortality among LT recipients[26]. The INR, a marker for coagulopathy, was one of the key components of both CLIF-C ACLFs and MELD, which emphasized the role of coagulopathy in forecasting the outcome of patients with liver disease [27]. Our study demonstrated that the predominant etiology related to HBV (84.1%) of ACLF had a critical role in improving survival rates, which is consistent with the previous study [28]. The liver is the major organ of bilirubin metabolism, and hepatocytes are the only cells that can produce DBiL[29]. In ACLF patients, the higher direct bilirubin suggested moderate hepatocyte damage, consistent with the fact that DBiL was negatively correlated with prognosis in our study. Hypolymphemia and neutropenia are physiological responses to adverse stressful events, which often predict adverse outcomes of LT with ACLF. Bing-Yi Lin et al. illustrated that a high neutrophil-lymphocyte ratio indicated poor prognosis for ACLF after LT [4].

Some limitations of the study should be mentioned. Firstly, our study was a single center retrospective study. Secondly, the lack of clinical donor data may have slightly influenced the analysis results. Additionally, the small number of cases may have slightly affected the performance of the machine learning techniques. Future large-scale and multicenter are required to evaluate whether better organ allocation by machine learning algorithms could promote transplant survival.

Conclusions

The ML models have good performance in predicting the short-term survival of ACLF patients following LT. The RF model best predicted the prognosis. With good predictive models, better organ allocation and clinical outcome can be achieved.

Declarations

Ethics approval and consent to participate

The study protocol complied with the standards of the Declaration of Helsinki and obtained approval from the Institutional Review Board of Third Xiangya Hospital, Central South University (No. 2020-S398). This was a minimal risk study and consent requirements waived as a result.

Consent for publication

All authors have given consent for publication.

Availability of data and materials

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Competing interests

None of the authors have competing interests to declare.

Funding

This study was supported by grants from the National Natural Science Foundation of China (81700658 and 81771722) and the Natural Science Foundation of Hunan

Authors' contributions

Yingzi Ming, Bo Peng and Min Yang conceived and designed the study. Min Yang collected the data. Min Yang and Yingzi Ming analyzed the data and wrote the manuscript. Quan Zhuang, Junhui Li, Hong Liu and Ke Cheng revised the manuscript. All authors read and approved the final manuscript.

Acknowledgements

There are no acknowledgements

Authors' information (optional)

Transplantation Center, Third Xiangya Hospital of Central South University, Changsha, Hunan, P.R. China

References

1. Arroyo V, Moreau R, Jalan R: **Acute-on-Chronic Liver Failure.** *The New England journal of medicine* 2020, **382**(22):2137–2145.
2. Sundaram V, Jalan R, Wu T, Volk M, Asrani S, Klein A, Wong R: **Factors Associated with Survival of Patients With Severe Acute-On-Chronic Liver Failure Before and After Liver Transplantation.** *Gastroenterology* 2019, **156**(5):1381-1391.e1383.
3. Levesque E, Winter A, Noorah Z, Daurès JP, Landais P, Feray C, Azoulay D: **Impact of acute-on-chronic liver failure on 90-day mortality following a first liver transplantation.** *Liver international: official journal of the International Association for the Study of the Liver* 2017, **37**(5):684–693.
4. Lin BY, Zhou L, Geng L, Zheng ZY, Jia JJ, Zhang J, Yao J, Zheng SS: **High neutrophil-lymphocyte ratio indicates poor prognosis for acute-on-chronic liver failure after liver transplantation.** *World journal of gastroenterology* 2015, **21**(11):3317–3324.
5. Benckert C, Quante M, Thelen A, Bartels M, Laudi S, Berg T, Kaisers U, Jonas S: **Impact of the MELD allocation after its implementation in liver transplantation.** *Scandinavian journal of gastroenterology* 2011, **46**(7-8):941–948.
6. Klein KB, Stafinski TD, Menon D: **Predicting survival after liver transplantation based on pre-transplant MELD score: a systematic review of the literature.** *PloS one* 2013, **8**(12):e80661.
7. Wagener G, Raffel B, Young AT, Minhaz M, Emond J: **Predicting early allograft failure and mortality after liver transplantation: the role of the postoperative model for end-stage liver disease score.** *Liver transplantation: official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society* 2013, **19**(5):534-542.
8. Jalan R, Saliba F, Pavesi M, Amoros A, Moreau R, Ginès P, Levesque E, Durand F, Angeli P, Caraceni P *et al*: **Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure.** *Journal of hepatology* 2014, **61**(5):1038–1047.
9. Engelmann C, Thomsen KL, Zakeri N, Sheikh M, Agarwal B, Jalan R, Mookerjee RP: **Validation of CLIF-C ACLF score to define a threshold for futility of intensive care support for patients with acute-on-chronic liver failure.** *Critical care (London, England)* 2018, **22**(1):254.
10. Chen BH, Tseng HJ, Chen WT: **Comparing Eight Prognostic Scores in Predicting Mortality of Patients with Acute-On-Chronic Liver Failure Who Were Admitted to an ICU: A Single-Center Experience.** *Journal of clinical medicine* 2020, **9**(5).
11. Spann A, Yasodhara A, Kang J, Watt K, Wang B, Goldenberg A, Bhat M: **Applying Machine Learning in Liver Disease and Transplantation: A Comprehensive Review.** *Hepatology (Baltimore, Md)* 2020, **71**(3):1093–1105.
12. Lau L, Kankanige Y, Rubinstein B, Jones R, Christophi C, Muralidharan V, Bailey J: **Machine-Learning Algorithms Predict Graft Failure After Liver Transplantation.** *Transplantation* 2017, **101**(4):e125-e132.
13. Liu CL, Soong RS, Lee WC, Jiang GW, Lin YC: **Predicting Short-term Survival after Liver Transplantation using Machine Learning.** *Scientific reports* 2020, **10**(1):5654.

14. Lee HC, Yoon SB, Yang SM, Kim WH: **Prediction of Acute Kidney Injury after Liver Transplantation: Machine Learning Approaches vs. Logistic Regression Model.** *Journal of clinical medicine* 2018, **7**(11).
15. Ayllón MD, Ciria R, Cruz-Ramírez M, Pérez-Ortiz M, Gómez I, Valente R, O'Grady J, de la Mata M, Hervás-Martínez C, Heaton ND *et al*: **Validation of artificial neural networks as a methodology for donor-recipient matching for liver transplantation.** *Liver transplantation: official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society* 2018, **24**(2):192–203.
16. Tang J, Liu R, Zhang YL, Liu MZ, Hu YF, Shao MJ, Zhu LJ, Xin HW, Feng GW, Shang WJ *et al*: **Application of Machine-Learning Models to Predict Tacrolimus Stable Dose in Renal Transplant Recipients.** *Scientific reports* 2017, **7**:42192.
17. Sarin SK, Choudhury A, Sharma MK, Maiwall R, Al Mahtab M, Rahman S, Saigal S, Saraf N, Soin AS, Devarbhavi H *et al*: **Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update.** *Hepatology international* 2019, **13**(4):353–390.
18. Peng B, Gong H, Tian H, Zhuang Q, Li J, Cheng K, Ming Y: **The study of the association between immune monitoring and pneumonia in kidney transplant recipients through machine learning models.** *Journal of translational medicine* 2020, **18**(1):370.
19. Deo SV, Al-Kindi SG, Altarabsheh SE, Hang D, Kumar S, Ginwalla MB, ElAmm CA, Sareyyupoglu B, Medalion B, Oliveira GH *et al*: **Model for end-stage liver disease excluding international normalized ratio (MELD-XI) score predicts heart transplant outcomes: Evidence from the registry of the United Network for Organ Sharing.** *The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation* 2016, **35**(2):222–227.
20. Chen L, Zheng J, Cai J, Jie Y, Zhang Y, Li H, Lu T, He L, Xiao C, Zeng K *et al*: **Predictive Value of Age-Bilirubin-International Normalized Ratio-Creatinine Score in Short-Term Survival of Acute-on-Chronic Hepatitis B Liver Failure.** *Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology* 2018, **51**(5):2484–2495.
21. Asrani S, Kim W: **Model for end-stage liver disease: end of the first decade.** *Clinics in liver disease* 2011, **15**(4):685–698.
22. Cabezu JB, Ramírez P, Ríos A, Acosta F, Torres D, Sansano T, Pons JA, Bru M, Montoya M, Bueno FS *et al*: **Risk factors of acute renal failure after liver transplantation.** *Kidney international* 2006, **69**(6):1073–1080.
23. Bahirwani R, Forde Ka Fau - Mu Y, Mu Y Fau - Lin F, Lin F Fau - Reese P, Reese P Fau - Goldberg D, Goldberg D Fau - Abt P, Abt P Fau - Reddy KR, Reddy Kr Fau - Levine M, Levine M: **End-stage renal disease after liver transplantation in patients with pre-transplant chronic kidney disease.** *Clin Transplant* 2014, **28**(1399-0012 (Electronic)):205-210.
24. Ding Y, Wu T, Zhang W, Zhang S, Wang W: **Pretransplant renal function evaluated by serum cystatin C was associated with mortality after liver transplantation: a single-center experience.** *Ann Transl*

- Med* 2019, **7**(2305–5839 (Print)):243.
25. Mantovani A, Zaza G, Byrne CD, Lonardo A, Zoppini G, Bonora E, Targher G: **Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis.** *Metabolism* 2018, **79**(1532–8600 (Electronic)):Metabolism, 2018, 2079: 2064–2076.
 26. VanWagner LB, Lapin B, Skaro AI, Lloyd-Jones DM, Rinella ME: **Impact of renal impairment on cardiovascular disease mortality after liver transplantation for nonalcoholic steatohepatitis cirrhosis.** *Liver international: official journal of the International Association for the Study of the Liver* 2015, **35**(1478-3231 (Electronic)):2575-2583.
 27. Rashidi-Alavijeh JA-O, Ceylan AS, Wedemeyer H, Kleefisch M, Willuweit K, Lange CM: **Standard coagulation tests are superior to thromboelastometry in predicting outcome of patients with liver cirrhosis.** *PloS one* 2020, **15**(1932–6203 (Electronic)):e0236528.
 28. Moon DB, Lee SG, Kang WH, Song GW, Jung DH, Park GC, Cho HD, Jwa EK, Kim WJ, Ha TY *et al*: **Adult Living Donor Liver Transplantation for Acute-on-Chronic Liver Failure in High-Model for End-Stage Liver Disease Score Patients.** *American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons* 2017, **17**(1600–6143 (Electronic)):1833–1842.
 29. Liu X, Zhang Y, Liu L, Pan Y, Hu Y, Yang P, Liao M: **Protective and therapeutic effects of nanoliposomal quercetin on acute liver injury in rats.** *BMC pharmacology & toxicology* 2020, **21**(1):11.

Tables

Table 1: Clinical characteristics of the patients

Characteristics	ALL(n=132)	Survival(n=113)	Death(n=19)	P value
Age, mean±SD (years)	45.92±11.07	45.50±11.04	48.37±11.26	0.30
HBV, n(%)	111(84.1%)	96(85.0%)	15(78.9%)	0.32
Male, n(%)	108(81.8%)	94(83.2%)	14(73.7%)	0.51
TBILI, mean±SD (μmol/L)	401.64±198.29	404.00±201.33	387.61±183.55	0.74
Cr, mean±SD (μmol/L)	84.71±51.07	78.23±37.09	123.26±92.67	0.05
INR, mean±SD	2.53±1.22	2.44±1.13	3.07±1.58	0.11
HE, n(%)	29(22.0%)	23(20.4%)	6(31.6%)	0.27
PT, mean±SD (s)	28.98±13.95	28.28±13.28	33.19±17.24	0.25
Urea, mean±SD (mmol/L)	7.83±11.60	7.04±11.20	12.54±13.11	0.06
Alb, mean±SD (g/L)	34.56±5.68	34.43±5.76	35.34±5.30	0.52
DBiL, mean±SD (μmol/L)	239.56±131.65	244.93±133.54	207.62±117.93	0.26
Hb, mean±SD (g/L)	105.07±23.52	105.44±23.19	102.90±25.98	0.67
Plt, mean±SD (10 ³ cells/μL)	92.53±78.81	93.78±82.80	85.05±49.73	0.66
WBC, mean±SD (10 ³ cells/μL)	8.06±4.42	7.80±4.19	9.59±5.49	0.10
LYM, mean±SD (10 ³ cells/μL)	1.09±0.77	1.12±0.78	0.92±0.70	0.31
NEUT, mean±SD (10 ³ cells/μL)	6.21±3.80	5.95±3.71	7.78±4.05	0.05

Tested by Student’s t-test or Pearson’s chi-squared (c2) test; Abbreviations: SD: Standard Deviation; HBV: Hepatitis B Virus; TBiL: total bilirubin; Cr: creatinine; INR: International Normalized Ratio; HE: hepatic encephalopathy; PT: prothrombin time; Alb: albumin; DBiL: Direct Bilirubin; Hb: hemoglobin; Plt: platelet; WBC: White Blood Cells; LYM: lymphocyte count; NEUT: neutrophil count.

Table 2: Univariate and multivariate Cox regression analyses of 90-day mortality

Characteristics	Univariate		Multivariate	
	P Value	HR (95%CI)	P Value	HR (95%CI)
Age, years	0.308	1.023(0.979~1.068)		
HBV	0.481	0.673(0.223~2.027)		
Male	0.354	0.617(0.222~1.714)		
TBILI, $\mu\text{mol/L}$	0.740	1.000(0.997~1.002)		
Cr, $\mu\text{mol/L}$	0.001	1.007(1.003~1.011)	0.030	1.006(1.001~1.011)
INR	0.034	1.347(1.023~1.773)	0.009	1.454(1.100~1.921)
HE	0.258	1.747(0.664~4.598)		
PT, s	0.152	1.019(0.993~1.045)		
Urea, mmol/L	0.071	1.019(0.998~1.040)	0.257	1.019(0.986~1.054)
Alb, g/L	0.507	1.026(0.950~1.109)		
DBiL, $\mu\text{mol/L}$	0.265	0.998(0.994~1.002)		
Hb, g/L	0.670	0.996(0.977~1.015)		
Plt, $10^3\text{cells}/\mu\text{L}$	0.664	0.999(0.992~1.005)		
WBC, $10^3\text{cells}/\mu\text{L}$	0.113	1.068(0.984~1.158)	0.284	0.743(0.431~1.279)
LYM, $10^3\text{cells}/\mu\text{L}$	0.317	0.692(0.336~1.424)		
NEUT, $10^3\text{cells}/\mu\text{L}$	0.060	1.095(0.996~1.203)	0.150	1.582(0.847~2.955)

Tested by univariate and multivariate Cox regression analysis; Abbreviations: HBV: Hepatitis B Virus; TBiL: total bilirubin; Cr: creatinine; INR: International Normalized Ratio; HE: hepatic encephalopathy; PT: [prothrombin time](#); Alb: albumin; DBiL: Direct Bilirubin; Hb: hemoglobin; Plt: platelet; WBC: White Blood Cells; LYM: lymphocyte count; NEUT: neutrophil count.

Table 3: Different scoring systems of the patients

Scoring systems	ALL(n=132)	Survival(n=113)	Death(n=19)	P Value
MELD Score, mean $\pm$ SD	24.69 $\pm$ 7.83	23.94 $\pm$ 7.44	29.13 $\pm$ 8.79	0.01
CLIF-OF, mediam(IQR)	9.5(8-11)	9(8-11)	10(9-13)	0.13
CLIF-C ACLFs, mean $\pm$ SD	42.57 $\pm$ 9.22	41.89 $\pm$ 9.19	46.62 $\pm$ 8.55	0.04
CLIF-SOFA, mediam(IQR)	8(7-10)	8(7-10)	9(7-12)	0.06
ABIC, mean $\pm$ SD	8.78 $\pm$ 1.85	8.66 $\pm$ 1.79	9.53 $\pm$ 2.06	0.06

Tested by Student’s t-test or Mann-Whitney U test; Abbreviations: SD: Standard Deviation; IQR: interquartile range; MELD: Model for end-stage liver disease; CLIF-SOFA: Chronic liver failure-Sequential organ failure assessment; CLIF-C OF: Chronic liver failure consortium Organ Failure score; ABIC: age-bilirubin-international normalized ratio-creatinine.

Table 4. The coefficients of the SVM and LR models

Parameters of models	SVM	LR
Cr	-4.24	-3.18
INR	-3.02	-2.12
HBV	1.43	0.76
DBiL	1.04	1.10
LYM	2.15	1.80
NEUT	-1.53	-1.43
Constant	0.29	0.31

Abbreviations: SVM, support vector machine; LR, logistic regression; Cr: creatinine; INR: International Normalized Ratio; HBV: Hepatitis B Virus; DBiL: Direct Bilirubin; LYM: lymphocyte count; NEUT: neutrophil count.

Figures

Figure 1

Flowchart of the search strategy and selection of studies for inclusion.

Figure 2

The overall survival curves of patients with the Kaplan–Meier estimator, tested with a log-rank test. (a) The overall survival curves of patients with different levels of Cr, P=0.008. (b) The overall survival curves of patients with different levels of INR, P=0.04. (c) The overall survival curves of patients with different levels of TBiL, P=0.49. (d) The overall survival curves of patients with different levels of Plt, P=0.41. (e) The overall survival curves of patients with different levels of WBC, P=0.71. Cr: creatinine; INR: International Normalized Ratio; TBiL: total bilirubin; Plt: platelet; WBC: White Blood Cells.

Figure 3

Scatter dot plot diagrams of the groups with conventional models to predict prognosis of ACLF following LT by Student's t-test or Mann-Whitney U test. The lines in the diagrams represent mean with SD. NS no significance * $P < 0.05$, ** $P < 0.01$. MELD: Model for end-stage liver disease; CLIF-SOFA: Chronic liver failure-Sequential organ failure assessment; CLIF-C OF: Chronic liver failure consortium Organ Failure score; ABIC: age-bilirubin-international normalized ratio-creatinine.

Figure 4

ROC curve comparison of conventional models to predict prognosis of ACLF following LT. MELD: Model for end-stage liver disease; CLIF-SOFA: Chronic liver failure-Sequential organ failure assessment; CLIF-C OF: Chronic liver failure consortium Organ Failure score; ABIC: age-bilirubin-international normalized ratio-creatinine.

Figure 5

The ROC curves and average AUC of the machine learning models. K-fold cross validation ($k = 5$) was used to estimate and compare the performance of different machine learning models. After five rounds of training/validation rotation, the average AUC was calculated. (a) The support vector machine (SVM) model. (b) The logistic regression (LR) model. (c) The multi-layer perceptron (MLP) model. (d) The random forest (RF) model. ROC curve, receiver operating characteristic curve. AUC, area under the curve

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SupplementTable.docx](#)